BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) EPS by Year
BCTXL
BriaCell Therapeutics Corp. Warrant expiring 2031 lost $62.19 per diluted share in fiscal year 2025. The table below carries 5 fiscal years, from 2021 to 2025, and the quarters BriaCell Therapeutics Corp. Warrant expiring 2031 has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
More BriaCell Therapeutics Corp. Warrant expiring 2031 financials
What was BriaCell Therapeutics Corp. Warrant expiring 2031's diluted earnings per share in fiscal year 2025?
BriaCell Therapeutics Corp. Warrant expiring 2031 lost $62.19 per diluted share in fiscal year 2025.
What was BriaCell Therapeutics Corp. Warrant expiring 2031's diluted earnings per share in the most recent quarter?
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported -$0.99 in diluted earnings per share in Q3 2026.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported on that line in every period on record.